RecruitingPhase 3NCT07670884

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.

Enrollment

675 participants

Start Date

Jul 17, 2026

Study Type

INTERVENTIONAL

Conditions

Chronic Management of Body Weight

Summary

This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HRS9531 Tablet and a drug called HRS9531 Tablet Placebo for people with chronic management of body weight. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHRS9531 Tablet

HRS9531 tablet.

DRUGHRS9531 Tablet Placebo

HRS9531 tablet placebo.

Locations(2)

Henan Provincial People's Hospital

Zhengzhou, Henan, China

Nanjing Drum Tower hospital

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07670884